MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

Join us at The Liver Meeting on Monday, November 10, 2025 (11:00 AM – 12:30 PM ET).
Illustrated portrait of Patrick ONeill, Head of Partnerships and Investor Relations of Model Medicines

Patrick ONeill

Head of Partnerships and Investor Relations

Dr. David (Davey) Smith will deliver the oral presentation titled “MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety” at The Liver Meeting hosted by American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., on Monday, November 10, 2025, from 11:00 AM to 12:30 PM ET.

Join us at The Liver Meeting on Monday, November 10, 2025 (11:00 AM – 12:30 PM ET).